{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:20:14Z","timestamp":1775474414146,"version":"3.50.1"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) has a rapidly growing incidence worldwide, affecting approximately one-third of world population. The disturbance of gut commensal bacteria impacting host\u2019s homeostasis is referred to as gut dysbiosis. The gut microbiome contributes to the pathogenesis of NAFLD through various pathways. Gut microbiota is at constant interactions with the intestinal epithelial barrier and affects its integrity. Through gut-liver axis, gut microbiota may influence liver immune function. The release of lipopolysaccharides (LPS) from intestines to portal vein which are transported to the liver, may trigger hepatic inflammation, steatosis and even fibrosis. Moreover, the gut microbiome induces the conversion of primary bile acids (BAs) to secondary BAs, which activates intestinal receptors, such as FXR and TGR5. FXR activation decreases fat absorption and thus reduces hepatic lipid accumulation, while TGR5 activation promotes the release of glucagon-like peptide-1 (GLP-1) in blood. Furthermore, gut ethanol-producing bacteria has been implicated in NAFLD development. Additionally, in NAFLD there is a reduction in intestinal levels of short-chain fatty acids, such as butyrate, propionate and acetate. Many bacterial alterations have been observed in NAFLD, including the increased <jats:italic>Bacteroidetes<\/jats:italic> and decreased <jats:italic>Firmicutes<\/jats:italic>. Many probiotics have been tried in NAFLD prevention and management, including a plethora of strains from <jats:italic>Lactobacilli<\/jats:italic>, <jats:italic>Bifidobacteria<\/jats:italic> and <jats:italic>Streptococcus<\/jats:italic> and some of them have promising perspectives. There is also some promising data from the administration of prebiotics (such as inulin and fructo-oligosaccharides) and symbiotics (probiotics plus prebiotics). Faecal microbiota transplantation (FMT) is yet to be evaluated for its efficacy against NAFLD.<\/jats:p>","DOI":"10.3389\/fgstr.2024.1534431","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:13:01Z","timestamp":1736835181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Gut microbiome in non-alcoholic fatty liver disease"],"prefix":"10.3389","volume":"3","author":[{"given":"Anastasios","family":"Mpountouridis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Tsigalou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Bezirtzoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Bezirtzoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Stavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-013-9468-6","article-title":"Immune and inflammatory pathways in NASH","author":"Ganz","year":"2013","journal-title":"Hepatol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0000000000000443","article-title":"Nonalcoholic fatty liver disease: A silent epidemic","volume":"42","author":"Sivell","year":"2019","journal-title":"Gastroenterol Nurs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: The growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.09.057","article-title":"The healthy microbiome-what is the definition of a healthy gut microbiome","volume":"160","author":"Shanahan","year":"2021","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002533","article-title":"Revised estimates for the number of human and bacteria cells in the body","volume":"14","author":"Sender","year":"2016","journal-title":"LoS Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","article-title":"A human gut microbial gene catalogue established by metagenomic sequencing","volume":"464","author":"Qin","year":"2010","journal-title":"Nature."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2022.02.023","article-title":"The gut microbiome","volume":"32","author":"Kuziel","year":"2022","journal-title":"Curr Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000720","article-title":"Gut microbiome and cardiovascular disease","volume":"35","author":"Zhao","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5145","article-title":"The role of the gut microbiome in systemic inflammatory disease","volume":"360","author":"Clemente","year":"2018","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56157","article-title":"High fat diet, gut microbiome and gastrointestinal cancer","volume":"11","author":"Tong","year":"2021","journal-title":"Theranostics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.1038\/s41598-017-13601-y","article-title":"Gut microbiome alterations in Alzheimer\u2019s disease","volume":"7","author":"Vogt","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2017-0072","article-title":"Gut microbiome and depression: what we know and what we need to know","volume":"29","author":"Winter","year":"2018","journal-title":"Rev Neurosci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.chom.2018.06.005","article-title":"Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome","volume":"24","author":"Ferretti","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270213","article-title":"Adaptation of the infant gut microbiome during the complementary feeding transition","volume":"17","author":"McKeen","year":"2022","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/0884533615609899","article-title":"Gut microbiome: what we do and don\u2019t know","volume":"30","author":"Cresci","year":"2015","journal-title":"Nutr Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2017.1373208","article-title":"Intestinal barrier and gut microbiota: Shaping our immune responses throughout life","volume":"5","author":"Takiishi","year":"2017","journal-title":"Tissue Barriers."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00048.2015","article-title":"Homeostasis of the gut barrier and potential biomarkers","volume":"312","author":"Wells","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri2707","article-title":"Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function","volume":"10","author":"Abreu","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.immuni.2014.12.028","article-title":"Antimicrobial defense of the intestine","volume":"42","author":"Mukherjee","year":"2015","journal-title":"Immunity."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40779-017-0122-9","article-title":"Interaction between the gut microbiome and mucosal immune system","volume":"4","author":"Shi","year":"2017","journal-title":"Mil Med Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/nu13051506","article-title":"Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms","volume":"13","author":"Altomare","year":"2021","journal-title":"Nutrients."},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH","volume":"11","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1748037","article-title":"Intestinal barrier dysfunction in fatty liver disease: roles of microbiota, mucosal immune system, and bile acids","volume":"42","author":"Gupta","year":"2022","journal-title":"Semin Liver Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.855008","article-title":"Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function","volume":"12","author":"Yu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10620-020-06100-0","article-title":"Fecal microbiota transplantation for chronic liver diseases: current understanding and future direction","author":"Lechner","year":"2020","journal-title":"Dig Dis Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2009.09.006","article-title":"Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice","volume":"10","author":"Saberi","year":"2009","journal-title":"Cell Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i2.109","article-title":"Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C","volume":"1426","author":"Tanwar","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-032521-102529","article-title":"Role of the inflammasome in liver disease","volume":"17","author":"de Carvalho Ribeiro","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J Lipid Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-019-0628-3","article-title":"Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome","volume":"7","author":"Song","year":"2019","journal-title":"Microbiome."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1864","article-title":"A biosynthetic pathway for a prominent class of microbiota-derived bile acids","volume":"11","author":"Devlin","year":"2015","journal-title":"Nat Chem Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S355","article-title":"Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration","author":"Staels","year":"2009","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1400327","article-title":"Cross-talk between bile acids and intestinal microbiota in host metabolism and health","volume":"16","author":"Nie","year":"2015","journal-title":"J Zhejiang Univ Sci B"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1159\/000450981","article-title":"Intestinal farnesoid X receptor and takeda G protein couple receptor 5 signaling in metabolic regulation","volume":"35","author":"Chiang","year":"2017","journal-title":"Dig Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319862691","article-title":"Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus","volume":"10","author":"Onoviran","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00060","article-title":"Attenuation of the hepatoprotective effects of ileal apical sodium dependent bile acid transporter (ASBT) inhibition in choline-deficient L-amino acid-defined (CDAA) diet-fed mice","volume":"7","author":"Rao","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.27635","article-title":"Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics","volume":"120","author":"Chen","year":"2019","journal-title":"J Cell Biochem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Del Chierico","year":"2017","journal-title":"Hepatology."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22627","article-title":"Chinese NAFLD clinical research network (CNAFLD CRN)Ratio of conjugated chenodeoxycholic to muricholic acids is associated with severity of nonalcoholic steatohepatitis. Obesity (Silver spring)","volume":"27","author":"Chen","year":"2019","journal-title":"Obesity A Res J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2131\/jts.45.87","article-title":"Taurine attenuates hepatic steatosis in a genetic model of fatty liver disease","volume":"45","author":"Miyata","year":"2020","journal-title":"J Toxicol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00256.2016","article-title":"Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon","volume":"312","author":"Ward","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goac037","article-title":"Co-administration of ursodeoxycholic acid with rosuvastatin\/ezetimibe in a non-alcoholic fatty liver disease model","volume":"10","author":"Seo","year":"2022","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.19267","article-title":"Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis","volume":"119","author":"Cope","year":"2000","journal-title":"Gastroenterology."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009570","article-title":"Role of alcohol metabolism in non-alcoholic steatohepatitis","volume":"5","author":"Baker","year":"2010","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.10.012","article-title":"Nonalcoholic fatty liver disease and the gut microbiome","volume":"20","author":"Boursier","year":"2016","journal-title":"Clin Liver Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1279354","article-title":"Increased fecal ethanol and enriched ethanol-producing gut bacteria Limosilactobacillus fermentum, Enterocloster bolteae, Mediterraneibacter gnavus and Streptococcus mutans in nonalcoholic steatohepatitis","volume":"13","author":"Mbaye","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02016-6","article-title":"Microbiome-derived ethanol in nonalcoholic fatty liver disease","volume":"28","author":"Meijnikman","year":"2022","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.007","article-title":"Dietary fiber and SCFAs in the regulation of mucosal immunity","volume":"151","author":"Tan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S0029665120006916","article-title":"SCFA: mechanisms and functional importance in the gut","volume":"80","author":"Martin-Gallausiaux","year":"2021","journal-title":"Proc Nutr Soc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114520000380","article-title":"Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism","volume":"123","author":"Amabebe","year":"2020","journal-title":"Br J Nutr"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.05.001","article-title":"Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber","volume":"17","author":"Chen","year":"2018","journal-title":"Clin Colorectal Cancer."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26030682","article-title":"The protective role of butyrate against obesity and obesity-related diseases","volume":"26","author":"Coppola","year":"2021","journal-title":"Molecules."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678360","article-title":"Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides","volume":"12","author":"Beisner","year":"2021","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3748\/wjg.v23.i1.60","article-title":"Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier","volume":"23","author":"Zhou","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000356211","article-title":"Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release","volume":"89","author":"Kaji","year":"2014","journal-title":"Digestion."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0183-1","article-title":"Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp Mol Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/nu12040951","article-title":"Oral supplementation of sodium butyrate attenuates the progression of non-alcoholic steatohepatitis","volume":"12","author":"Baumann","year":"2020","journal-title":"Nutrients."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.211","article-title":"Endocannabinoids\u2013at the crossroads between the gut microbiota and host metabolism","volume":"12","author":"Cani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051554","article-title":"Obesity affects the microbiota-gut-brain axis and the regulation thereof by endocannabinoids and related mediators","volume":"21","author":"Forte","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/msb.2010.46","article-title":"The endocannabinoid system links gut microbiota to adipogenesis","volume":"6","author":"Muccioli","year":"2010","journal-title":"Mol Syst Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055963","article-title":"Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia","volume":"8","author":"Geurts","year":"2013","journal-title":"PloS One"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00867-z","article-title":"Gut microbiota in overweight and obesity: crosstalk with adipose tissue","volume":"21","author":"Cani","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.159056","article-title":"Exploring the endocannabinoidome in genetically obese (ob\/ob) and diabetic (db\/db) mice: Links with inflammation and gut microbiota","volume":"1867","author":"Suriano","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"key":"B91","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41467-018-08051-7","article-title":"Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis","volume":"10","author":"Everard","year":"2019","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e32834e7b4b","article-title":"Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression","volume":"28","author":"Corbin","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00344.2019","article-title":"Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH","volume":"318","author":"Hernandez","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/nu12082340","article-title":"The relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases","volume":"12","author":"Arias","year":"2020","journal-title":"Nutrients."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-023-01336-1","article-title":"Dietary choline intake and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2017-2018","volume":"77","author":"Chai","year":"2023","journal-title":"Eur J Clin Nutr"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00225.2013","article-title":"Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model","volume":"305","author":"Okubo","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175406","article-title":"Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis","volume":"12","author":"Matsumoto","year":"2017","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2021.1966738","article-title":"Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis","volume":"63","author":"Han","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.206","article-title":"The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis","volume":"48","author":"Wigg","year":"2001","journal-title":"Gut."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1447-3","article-title":"Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8","volume":"56","author":"Shanab","year":"2011","journal-title":"Dig Dis Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/srep32002","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics","volume":"12","author":"Wong","year":"2013","journal-title":"A proof-of-concept study. Ann Hepatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.844374","article-title":"Hepatoprotection of probiotics against non-alcoholic fatty liver disease in vivo: A systematic review","volume":"9","author":"Sabirin","year":"2022","journal-title":"Front Nutr"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16645055","article-title":"Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease","volume":"9","author":"Briskey","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.010","article-title":"Lactococcus lactis Subspecies cremoris Elicits Protection Against Metabolic Changes Induced by a Western-Style Diet","volume":"159","author":"Naudin","year":"2020","journal-title":"Gastroenterology."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2012.01.014","article-title":"Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model","volume":"24","author":"Wagnerberger","year":"2013","journal-title":"J Nutr Biochem"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20330","article-title":"Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice","volume":"21","author":"Cano","year":"2013","journal-title":"Obes (Silver Spring)."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-10633-9","article-title":"Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation","volume":"104","author":"Zhao","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/nu12020542","article-title":"Beneficial effects of lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat\/high fructose diet-fed rats","volume":"12","author":"Park","year":"2020","journal-title":"Nutrients."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01804","article-title":"Protective Effect of Akkermansia muciniphila against Immune-Mediated Liver Injury in a Mouse Model","volume":"8","author":"Wu","year":"2017","journal-title":"Front Microbiol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e80169","DOI":"10.1371\/journal.pone.0080169","article-title":"Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice","volume":"9","author":"Ritze","year":"2014","journal-title":"PloS One"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.03.107","article-title":"Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice","volume":"473","author":"Kim","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2019.108256","article-title":"Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice","volume":"75","author":"Liu","year":"2020","journal-title":"J Nutr Biochem"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3770-1","article-title":"Lactobacillus paracasei induces M2-dominant kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis","volume":"60","author":"Sohn","year":"2015","journal-title":"Dig Dis Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-014-5752-1","article-title":"Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice","volume":"98","author":"Xin","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2019.09.07","article-title":"Probiotics VSL3 are effective in reversing non-alcoholic steatohepatitis in a mouse model","volume":"9","author":"Jena","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: The beneficial effects of VSL3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"B126","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/srep45176","article-title":"Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia","volume":"7","author":"Xue","year":"2017","journal-title":"Sci Rep"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2016391","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063167","article-title":"Usefulness of probiotics in the management of NAFLD: evidence and involved mechanisms of action from preclinical and human models","volume":"23","author":"Arellano-Garc\u00eda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182827","article-title":"Age-related NAFLD: the use of probiotics as a supportive therapeutic intervention","volume":"11","author":"Campagnoli","year":"2022","journal-title":"Cells."},{"key":"B134","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/foods8030092","article-title":"Prebiotics: definition, types, sources, mechanisms, and clinical applications","volume":"8","author":"Davani-Davari","year":"2019","journal-title":"Foods."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-31248-4_9","article-title":"How to manipulate the microbiota: prebiotics","volume":"902","author":"Louis","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12876-020-01194-2","article-title":"Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis","volume":"20","author":"Takai","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519896714","article-title":"Fructo-oligosaccharides lower serum lipid levels and suppress high-fat\/high-sugar diet-induced inflammation by elevating serum and gut levels of short-chain fatty acids","volume":"48","author":"Yu","year":"2020","journal-title":"J Int Med Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/NMI.S24385","article-title":"Choline and fructooligosaccharide: non-alcoholic fatty liver disease, cardiac fat deposition, and oxidative stress markers","volume":"8","author":"Borges Haubert","year":"2015","journal-title":"Nutr Metab Insights"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201200364","article-title":"Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways","volume":"57","author":"Pachikian","year":"2013","journal-title":"Mol Nutr Food Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2015.03.010","article-title":"Effects of dietary inulin on bacterial growth, short-chain fatty acid production and hepatic lipid metabolism in gnotobiotic mice","volume":"26","author":"Weitkunat","year":"2015","journal-title":"J Nutr Biochem"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/nu12040937","article-title":"Randomised double-blind placebo-controlled trial of inulin with metronidazole in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Chong","year":"2020","journal-title":"Nutrients."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602127","article-title":"Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"59","author":"Daubioul","year":"2005","journal-title":"Eur J Clin Nutr"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2022.112309","article-title":"Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function","volume":"163","author":"Yang","year":"2023","journal-title":"Food Res Int"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.02.033","article-title":"Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice","volume":"600","author":"Wang","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020991","article-title":"Inulin improves diet-induced hepatic steatosis and increases intestinal akkermansia genus level","volume":"23","author":"P\u00e9rez-Monter","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/nu16111571","article-title":"Prebiotic treatment in patients with nonalcoholic fatty liver disease (NAFLD)-A randomized pilot trial","volume":"16","author":"Reshef","year":"2024","journal-title":"Nutrients."},{"key":"B148","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41575-020-0344-2","article-title":"The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics","volume":"17","author":"Swanson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Dig Dis Sci"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201600622","article-title":"A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota","volume":"61","author":"Rivero-Guti\u00e9rrez","year":"2017","journal-title":"Mol Nutr Food Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3109\/09637486.2013.775224","article-title":"The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial","volume":"64","author":"Safavi","year":"2013","journal-title":"Int J Food Sci Nutr"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3920\/BM2015.0011","article-title":"Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children","volume":"6","author":"Ipar","year":"2015","journal-title":"Benef Microbes"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02010","article-title":"Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver","volume":"8","author":"Alves","year":"2017","journal-title":"Front Microbiol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"107398","DOI":"10.1016\/j.phrs.2024.107398","article-title":"The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Musazadeh","year":"2024","journal-title":"Pharmacol Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05699-z","article-title":"Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"64","author":"Liu","year":"2019","journal-title":"Dig Dis Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.86611","article-title":"Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease","volume":"15","author":"Yao","year":"2019","journal-title":"Arch Med Sci"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155759","article-title":"Markers of adipose tissue fibrogenesis associate with clinically significant liver fibrosis and are unchanged by synbiotic treatment in patients with NAFLD","volume":"151","author":"Bilson","year":"2024","journal-title":"Metabolism."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology."},{"key":"B160","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-024-03356-y","article-title":"Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pan","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1293223","article-title":"A proposed definition of microbiota transplantation for regulatory purposes","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Gut Microbes"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013871.pub2","article-title":"Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.infpip.2020.100069","article-title":"Regulation, risk and safety of Faecal Microbiota Transplant","volume":"2","author":"Merrick","year":"2020","journal-title":"Infect Prev Pract"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1601","article-title":"Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1534431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:13:06Z","timestamp":1736835186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2024.1534431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":167,"alternative-id":["10.3389\/fgstr.2024.1534431"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2024.1534431","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1534431"}}